Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system. J Clin Oncol 2004; 14: 2865-72.10.1200/JCO.2004.12.149Search in Google Scholar

2. Smedby KE, Brandt L, Backlund ML, Blomqvist P. Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 2009; 11: 1919-24.10.1038/sj.bjc.6605373Search in Google Scholar

3. Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002; 1: 53-7.10.1016/S1470-2045(01)00622-2Search in Google Scholar

4. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 8: 1295-304.10.1200/JCO.2005.04.6185Search in Google Scholar

5. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neuro-Oncol 1999; 3: 275-81.10.1023/A:1006308808769Search in Google Scholar

6. Li J, Bentzen SM, Li JL, Renschler M, Mehta MP. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int J Radiat Oncol Biol Physics 2008; 1: 64-70.10.1016/j.ijrobp.2007.09.059Search in Google Scholar

7. Lekic M, Kovac V, Triller N, Knez L, Sadikov A, Cufer T. Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting. Radiol Oncol 2012; 1: 54-9.10.2478/v10019-012-0007-1Search in Google Scholar

8. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases - Histology, multiplicity, surgery, and survival. Cancer 1996; 8: 1781-8.10.1002/(SICI)1097-0142(19961015)78:8<1781::AID-CNCR19>3.0.CO;2-USearch in Google Scholar

9. Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007; 10: 1260-6.10.1200/JCO.2006.09.2536Search in Google Scholar

10. Agerholm-Larsen B, Iversen HK, Ibsen P, Moller JM, Mahmood F, Jensen KS, et al. Preclinical validation of electrochemotherapy as an effective treatment for brain tumors. Cancer Res 2011; 11: 3753-62.10.1158/0008-5472.CAN-11-0451Search in Google Scholar

11. Bhangoo SS, Linskey ME, Kalkanis SN. Evidence-based guidelines for the management of brain metastases. Neurosurg Clin N Am 2011; 1: 97-+.10.1016/j.nec.2010.09.001Search in Google Scholar

12. Jenkinson MD, Haylock B, Shenoy A, Husband D, Javadpour M. Management of cerebral metastasis: Evidence-based approach for surgery, stereotactic radiosurgery and radiotherapy. Eur J Cancer 2011; 5: 649-55.10.1016/j.ejca.2010.11.033Search in Google Scholar

13. Stanic K, Kovac V. Prophylactic cranial irradiation in patients with small-cell lung cancer: the experience at the Institute of Oncology Ljubljana. Radiol Oncol 2010; 3: 180-6.10.2478/v10019-010-0038-4Search in Google Scholar

14. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009; 11: 1037-44.10.1016/S1470-2045(09)70263-3Search in Google Scholar

15. Videtic GM, Gaspar LE, Aref AM, Germano IM, Goldsmith BJ, Imperato JP, et al. American College of Radiology appropriateness criteria on multiple brain metastases. Int J Radiat Oncol Biol Phys 2009; 4: 961-5.10.1016/j.ijrobp.2009.07.172019857783Search in Google Scholar

16. Kalkanis SN, Kondziolka D, Gaspar LE, Burri SH, Asher AL, Cobbs CS, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol 2010; 1: 33-43.10.1007/s11060-009-0061-8280851619960230Search in Google Scholar

17. Patchell RA, Regine WF. The rationale for adjuvant whole brain radiation therapy with radiosurgery in the treatment of single brain metastases. Technol Cancer Res Treatm 2003; 2: 111-5.10.1177/15330346030020020612680791Search in Google Scholar

18. Bahl A, Kumar M, Sharma DN, Basu KSJ, Jaura MS, Rath GK, et al. Reirradiation for progressive brain metastases. J Cancer Res Ther 2009; 3: 161-4.10.4103/0973-1482.5712019841556Search in Google Scholar

19. Hazuka MB, Kinzie JJ. Brain metastases - results and effects of re-irradiation. Int J Radiat Oncol Biol Phys 1988; 2: 433-7.Search in Google Scholar

20. Addeo R, Caraglia M, Faiola V, Capasso E, Vincenzi B, Montella L, et al. Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life. Bmc Cancer 2007.10.1186/1471-2407-7-18179425317254350Search in Google Scholar

21. Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 2004; 11: 2101-7.10.1200/JCO.2004.11.04415169796Search in Google Scholar

22. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005; 10: 987-96.10.1056/NEJMoa04333015758009Search in Google Scholar

23. Verger E, Miguel G, Yaya R, Vinolas N, Villa S, Pujol T, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial. Int J Radiat Oncol Biol Phys 2005; 1: 185-91.10.1016/j.ijrobp.2004.04.06115629610Search in Google Scholar

24. Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, et al. The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neuro-Oncol 2010; 1: 71-83.10.1007/s11060-009-0062-7280851819960229Search in Google Scholar

25. Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, et al. Phase II Randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002; 17: 3644-50.10.1200/JCO.2002.04.14012202665Search in Google Scholar

26. Rivera E, Meyers C, Groves M, Valero V, Francis D, Arun B, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 2006; 6: 1348-54.10.1002/cncr.2212716909414Search in Google Scholar

27. Newton HB, Slivka MA, Volpi C, Bourekas EC, Christoforidis GA, Baujan MA, et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of metastatic brain tumors. J Neuro-Oncol 2003; 1: 35-44.10.1023/A:1021218207015Search in Google Scholar

28. Kiewe P, Thiel E, Reinwald M, Korfel A. Topotecan and ifosfamide systemic chemotherapy for CNS involvement of solid tumors. J Neuro-Oncol 2011; 3: 629-34.10.1007/s11060-010-0434-z20941526Search in Google Scholar

29. Addeo R, Caraglia M. The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer? Expert Review Anticancer Ther 2011; 2: 139-42.Search in Google Scholar

30. Lin NU, Carey LA, Liu MC, Younger J, Come SE, Ewend M, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008; 12: 1993-9.10.1200/JCO.2007.12.3588452435118421051Search in Google Scholar

31. Lin NU, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009; 4: 1452-9.10.1158/1078-0432.CCR-08-108019228746Search in Google Scholar

32. Gore ME, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason GA, et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011; 3: 501-9.10.1002/cncr.2545220862748Search in Google Scholar

33. Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 11: 1810-16.10.1200/JCO.2007.14.5375Search in Google Scholar

34. Novello S, Camps C, Grossi F, Mazieres J, Abrey L, Vernejoux JM, et al. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. J Thorac Oncol 2011; 7: 1260-6.10.1097/JTO.0b013e318219a973Search in Google Scholar

35. Franceschi E, Brandes AA. Brain metastases from non-small-cell lung cancer: is there room for improvement? Exp Rev Anticancer Ther 2012; 4: 421-3.Search in Google Scholar

36. Porta R, Sanchez-Torres JM, Paz-Ares L, Massuti B, Reguart N, Mayo C, et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011; 3: 624-31.10.1183/09031936.00195609Search in Google Scholar

37. Labidi SI, Bachelot T, Ray-Coquard I, Mosbah K, Treilleux I, Fayette J, et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: A case series. Clin Breast Cancer 2009; 2: 118-21.10.3816/CBC.2009.n.021Search in Google Scholar

38. Gehl J, Sorensen TH, Nielsen K, Raskmark P, Nielsen SL, Skovsgaard T, et al. In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta 1999; 2-3: 233-40.10.1016/S0304-4165(99)00094-XSearch in Google Scholar

39. Tounekti O, Kenani A, Foray N, Orlowski S, Mir LM. The ratio of single- to double-strand DNA breaks and their absolute values determine cell death pathway. Br J Cancer 2001; 9: 1272-79.10.1054/bjoc.2001.1786Search in Google Scholar

40. Orlowski S, Belehradek J, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture - Increase of the cyto-toxicity of anticancer drugs. Biochem Pharmacol 1988; 24: 4727-33.10.1016/0006-2952(88)90344-9Search in Google Scholar

41. Gothelf A, Mir LM, Gehl J. Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003; 5: 371-87.10.1016/S0305-7372(03)00073-2Search in Google Scholar

42. Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator (TM) by means of invasive or non-invasive electrodes. EJC Suppl 2006; 11: 14-25.10.1016/j.ejcsup.2006.08.003Search in Google Scholar

43. Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anti-Cancer Drug 1998; 4: 319-25.10.1097/00001813-199804000-000059635922Search in Google Scholar

44. Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. Anti-Cancer Drug 2000; 3: 201-8.10.1097/00001813-200003000-00008Search in Google Scholar

45. Matthiessen LW, Chalmers RL, Sainsbury DCG, Veeramani S, Kessell G, Humphreys AC, et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011; 5: 621-9.10.3109/0284186X.2011.573626Search in Google Scholar

46. Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998; 1: 148-57.10.1002/(SICI)1097-0142(19980701)83:1<148::AID-CNCR20>3.0.CO;2-WSearch in Google Scholar

47. Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, et al. Electrochemotherapy - An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 2006; 11: 3-13.10.1016/j.ejcsup.2006.08.002Search in Google Scholar

48. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J, Mir LM. Electrochemotherapy, a new antitumor treatment - 1st clinical phase-I-Ii trial. Cancer 1993; 12: 3694-700.10.1002/1097-0142(19931215)72:12<3694::AID-CNCR2820721222>3.0.CO;2-2Search in Google Scholar

49. Gehl J. Investigational treatment of cancer using electrochemotherapy, electrochemoimmunotherapy and electro-gene transfer. Ugeskr Laeger 2005; 34: 3156-9.Search in Google Scholar

50. Gehl J, Skovsgaard T, Mir LM. Vascular reactions to in vivo electroporation: characterization and consequences for drug and gene delivery. Biochim Biophys Acta 2002; 1-3: 51-8.10.1016/S0304-4165(01)00233-1Search in Google Scholar

51. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma. Brit J Cancer 2008; 2: 388-98.10.1038/sj.bjc.6604168Search in Google Scholar

52. Soden D, Morrissey A, Collins C, Piggott J, Larkin J, Norman A, et al. Electrotherapy of tumour cells using flexible electrode arrays. Sensor Actual B-Chem 2004; 1-2: 219-24.10.1016/j.snb.2004.04.087Search in Google Scholar

53. Mahmood F, Gehl J. Optimizing clinical performance and geometrical robustness of a new electrode device for intracranial tumor electroporation. Bioelectrochemistry 2011; 1: 10-6.10.1016/j.bioelechem.2010.12.002Search in Google Scholar

54. Edhemovic I, Gadzijev EM, Brecelj E, Miklavcic D, Kos B, Zupanic A, et al. Electrochemotherapy: a new technological approach in treatment of metastases in the liver. Technol Cancer Res Treatm 2011; 5: 475-85.10.7785/tcrt.2012.500224Search in Google Scholar

55. Salford LG, Persson BR, Brun A, Ceberg CP, Kongstad PC, Mir LM. A new brain tumour therapy combining bleomycin with in vivo electropermeabilization. Biochem Biophys Res Commun 1993; 2: 938-43.10.1006/bbrc.1993.19117688229Search in Google Scholar

56. Agerholm-Larsen B, Iversen HK, Moller J, Ibsen P, Jensen KS, Linnert M, et al. Effect of electrochemotherapy with IV bleomycin on complete response in a preclinical brain tumor study. J Clin Oncol 2012, 30: abstr 2069.10.1200/jco.2012.30.15_suppl.2069Search in Google Scholar

57. Linnert M, Gehl J. Bleomycin treatment of brain tumors: an evaluation. Anti-Cancer Drugs 2009; 3: 157-64.10.1097/CAD.0b013e328325465e19396014Search in Google Scholar

58. Osanto S, Bukman A, Vanhoek F, Sterk PJ, Delaat JAPM, Hermans J. Longterm effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992; 4: 574-9.10.1200/JCO.1992.10.4.5741372350Search in Google Scholar

59. Pliarchopoulou K, Pectasides D. Late complications of chemotherapy in testicular cancer. Cancer Treatm Rev 2010; 3: 262-7.10.1016/j.ctrv.2009.12.01120092952Search in Google Scholar